Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539406 | 0.89 | PPARD (0.37) | PPARDNR1H2PTGS2PPARA | |
| SCHEMBL6538964 | 0.85 | PPARD (0.39) | PPARDKDM4EALDH1A1PTGS2PTGER4 | |
| SCHEMBL6540424 | 0.85 | ALDH1A1 (0.42) | PPARDKDM4EALDH1A1POLBMAPT | |
| SCHEMBL6539669 | 0.84 | KDM4E (0.41) | PPARDKDM4EALDH1A1POLBMAPT | |
| SCHEMBL6539799 | 0.83 | ALDH1A1 (0.40) | PPARDKDM4EALDH1A1POLBMAPT | |
| SCHEMBL6275665 | 0.83 | PPARD (0.38) | PPARDKDM4EALDH1A1POLBMAPT | |
| SCHEMBL6207503 | 0.82 | PPARD (0.40) | PPARDKDM4EALDH1A1HPGDPTGS2 | |
| SCHEMBL6539395 | 0.81 | POLB (0.41) | PPARDKDM4EPOLBMAPT | |
| SCHEMBL6539135 | 0.80 | PPARD (0.39) | PPARDPTGS2PPARA | |
| SCHEMBL6539743 | 0.79 | PPARD (0.38) | PPARDPTGS2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583749-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | Astellas Pharma Inc. (JP) | 2005-10-12 | — | — | EP | disclosed |
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| WO-2004065374-A1 | OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE | ASTELLAS PHARMA INC. (JP) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | PPARD 1747/4885KDM4E 1912/4885ALDH1A1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.